Docetaxel-Induced Stevens-Johnson Syndrome in a Patient with Metastatic Prostate Adenocarcinoma.

Autor: Diab O; Department of Medicine, Creighton University, Omaha, NE, USA., Mcentire D; Department of Medicine, University of Utah, Salt Lake City, UT, USA., Kassim T; Department of Medicine, Creighton University, Omaha, NE, USA., Nayfeh A; Department of Medicine, Creighton University, Omaha, NE, USA., Dajani AR; Department of Medicine, Norwalk Hospital, Norwalk, CT, USA., Kerfeld M; Department of Pathology, Creighton University, Omaha, NE, USA., Campbell J; Department of Medicine, Creighton University, Omaha, NE, USA., Alsuwaidan A; Department of Anesthesia, Mayo Clinic, Rochester, MN, USA., Hazeem MA; Department of Medicine, Creighton University, Omaha, NE, USA., Gbadamosi-Akindele M; Department of Medicine, Creighton University, Omaha, NE, USA.
Jazyk: angličtina
Zdroj: Case reports in oncological medicine [Case Rep Oncol Med] 2019 Jan 08; Vol. 2019, pp. 7928752. Date of Electronic Publication: 2019 Jan 08 (Print Publication: 2019).
DOI: 10.1155/2019/7928752
Abstrakt: Docetaxel is a commonly used chemotherapeutic agent in a variety of cancer treatment regimens. We present a case of apparent docetaxel-induced Stevens-Johnson syndrome (SJS) in a patient recently treated for metastatic prostate cancer. This medication is not classically associated with the development of SJS but in our case, along with a number of other case reports, and a single phase II clinical trial, an association was recognized. We encourage clinicians who employ the use of this medication to be aware of this relationship.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje